Gilead partners with a cancer biotech, seeking to develop an HIV immunotherapy

Gilead will partner with a small Californian biotech to develop an immunotherapy for HIV, announcing Monday a collaboration-and-option deal with the company, Gritstone Oncology, that could be worth hundreds of millions of dollars.